Evidence map›Paper›PMID 27279606›Full record

ArticleJournal of virology2016

Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors.

Lorenzo Bulli, Luis Apolonia, Juliane Kutzner, Darja Pollpeter, Caroline Goujon, Nikolas Herold, Sarah-Marie Schwarz, Yannick Giernat, Oliver T Keppler, Michael H Malim and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Antiviral Properties of HIV-1 Capsid Inhibitor GSK878.Antimicrobial agents and chemotherapy · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Lorenzo BulliDepartment of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany.
Luis ApoloniaDepartment of Infectious Diseases, King's College London, London, United Kingdom.
Juliane KutznerDepartment of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany.
Darja PollpeterDepartment of Infectious Diseases, King's College London, London, United Kingdom.
Caroline GoujonDepartment of Infectious Diseases, King's College London, London, United Kingdom.
Nikolas HeroldInstitute for Medical Virology, University Hospital Frankfurt/Main, Frankfurt, Germany.
Sarah-Marie SchwarzInstitute for Medical Virology, University Hospital Frankfurt/Main, Frankfurt, Germany.
Yannick GiernatInstitute for Medical Virology, University Hospital Frankfurt/Main, Frankfurt, Germany.
Oliver T KepplerInstitute for Medical Virology, University Hospital Frankfurt/Main, Frankfurt, Germany.
Michael H MalimDepartment of Infectious Diseases, King's College London, London, United Kingdom michael.malim@kcl.ac.uk torsten.schaller@med.uni-heidelberg.de.
Torsten SchallerDepartment of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany michael.malim@kcl.ac.uk torsten.schaller@med.uni-heidelberg.de.
King's College London · GBUniversity Hospital Frankfurt · DEGoethe University Frankfurt · DEHeidelberg University · DEKarolinska University Hospital · SE

Funding

A Systems-level Approach to Studying HIV/AIDS Susceptibility and Substance AbuseR01DA033773 · NIDA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WOLINSKY, STEVEN M · 2012 to 2016
$4.6M
ERB-B ACTIVATION: FROM EGF-RECEPTOR TO LEUKEMIA ONCOGENEK08CA001199 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI PELLEY, ROBERT J · 1987 to 1991
–
Department of Health GUYSBRC-2012-1Medical Research Council G1000196Medical Research Council MR/M001199/1NIDA NIH HHS R01 DA033773Wellcome TrustWellcome Trust 106223/Z/14/Z
6 · The paper itself

Abstract

unlabelledType I interferons (IFNs), including IFN-α, upregulate an array of IFN-stimulated genes (ISGs) and potently suppress Human immunodeficiency virus type 1 (HIV-1) infectivity in CD4(+) T cells, monocyte-derived macrophages, and dendritic cells. Recently, we and others identified ISG myxovirus resistance 2 (MX2) as an inhibitor of HIV-1 nuclear entry. However, additional antiviral blocks exist upstream of nuclear import, but the ISGs that suppress infection, e.g., prior to (or during) reverse transcription, remain to be defined. We show here that the HIV-1 CA mutations N74D and A105T, both of which allow escape from inhibition by MX2 and the truncated version of cleavage and polyadenylation specific factor 6 (CPSF6), as well as the cyclophilin A (CypA)-binding loop mutation P90A, all increase sensitivity to IFN-α-mediated inhibition. Using clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 technology, we demonstrate that the IFN-α hypersensitivity of these mutants in THP-1 cells is independent of MX2 or CPSF6. As expected, CypA depletion had no additional effect on the behavior of the P90A mutant but modestly increased the IFN-α sensitivity of wild-type virus. Interestingly, the infectivity of wild-type or P90A virus could be rescued from the MX2-independent IFN-α-induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-α-induced blocks. We propose that cellular interactions with incoming HIV-1 capsids help shield the virus from recognition by antiviral effector mechanisms. Thus, the CA protein is a fulcrum for the dynamic interplay between cell-encoded functions that inhibit or promote HIV-1 infection. IMPORTANCE: HIV-1 is the causative agent of AIDS. During acute HIV-1 infection, numerous proinflammatory cytokines are produced, including type I interferons (IFNs). IFNs can limit HIV-1 replication by inducing the expression of a set of antiviral genes that inhibit HIV-1 at multiple steps in its life cycle, including the postentry steps of reverse transcription and nuclear import. This is observed in cultured cell systems, as well as in clinical trials in HIV-1-infected patients. The identities of the cellular antiviral factors, their viral targets, and the underpinning mechanisms are largely unknown. We show here that the HIV-1 Capsid protein plays a central role in protecting the virus from IFN-induced inhibitors that block early postentry steps of infection. We further show that host cell cyclophilins play an important role in regulating these processes, thus highlighting the complex interplay between antiviral effector mechanisms and viral survival.

Indexed as

Host-Pathogen InteractionsAntiviral AgentsCell LineHIV-1HIV Core Protein p24HumansImmunity, InnateImmunologic FactorsInterferon-alphaMonocytesMutant ProteinsAntiviral AgentsHIV Core Protein p24Immunologic FactorsInterferon-alphaMutant Proteins

Identifiers

PMID27279606
PMCPMC4984639
OpenAlexW2489639916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.